This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetics Of Celecoxib Test Formulations

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: June 18, 2009
Last updated: August 19, 2010
Last verified: August 2010
The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.

Condition Intervention Phase
Healthy Volunteers Drug: Celebrex capsule Drug: Test formulation D1 Drug: Test formulation D2 Drug: Test formulation D3 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Celecoxib Formulations D1, D2 And D3 In Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • AUCinf, AUCt, Cmax [ Time Frame: 1.5 month ]
  • Visual inspection of median plasma concentration versus time profiles resulting from each formulation [ Time Frame: 1.5 month ]

Secondary Outcome Measures:
  • Tmax, half-life [ Time Frame: 1.5 month ]
  • adverse events, laboratory tests, vital signs [ Time Frame: 1.5 month ]

Enrollment: 16
Study Start Date: July 2009
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Celebrex capsule
Commercial capsule
Drug: Celebrex capsule
Single dose 200 mg commercial Celebrex capsule
Experimental: D1
Test formulation D1
Drug: Test formulation D1
Single dose 150 mg celecoxib as formulation D1
Experimental: D2
Test formulation D2
Drug: Test formulation D2
Single dose 150 mg celecoxib as formulation D2
Experimental: D3
Test formulation D3
Drug: Test formulation D3
Single dose 150 mg celecoxib as formulation D3


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female volunteers
  • Body weight BMI 17.5-30.5

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
  • Positive urine drug screen
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00925106

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511-5473
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00925106     History of Changes
Other Study ID Numbers: A3191355
Study First Received: June 18, 2009
Last Updated: August 19, 2010

Keywords provided by Pfizer:
Bioavailability, pharmacokinetics, celecoxib

Additional relevant MeSH terms:
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on September 21, 2017